- Home
- PHIO vs GSIW Comparison
PHIO vs GSIW Comparison
Compare PHIO & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- GSIW
- Stock Information
- Founded
- PHIO 2011
- GSIW 2016
- Country
- PHIO United States
- GSIW Hong Kong
- Employees
- PHIO N/A
- GSIW N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- PHIO Health Care
- GSIW
- Exchange
- PHIO Nasdaq
- GSIW Nasdaq
- Market Cap
- PHIO 8.6M
- GSIW 8.3M
- IPO Year
- PHIO N/A
- GSIW 2023
- Fundamental
- Price
- PHIO $2.00
- GSIW $0.72
- Analyst Decision
- PHIO Strong Buy
- GSIW
- Analyst Count
- PHIO 1
- GSIW 0
- Target Price
- PHIO $4.00
- GSIW N/A
- AVG Volume (30 Days)
- PHIO 875.3K
- GSIW 2.0M
- Earning Date
- PHIO 05-15-2025
- GSIW 12-31-2024
- Dividend Yield
- PHIO N/A
- GSIW N/A
- EPS Growth
- PHIO N/A
- GSIW N/A
- EPS
- PHIO N/A
- GSIW N/A
- Revenue
- PHIO N/A
- GSIW $1,313,795.00
- Revenue This Year
- PHIO N/A
- GSIW N/A
- Revenue Next Year
- PHIO N/A
- GSIW N/A
- P/E Ratio
- PHIO N/A
- GSIW N/A
- Revenue Growth
- PHIO N/A
- GSIW N/A
- 52 Week Low
- PHIO $0.97
- GSIW $0.35
- 52 Week High
- PHIO $9.79
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- PHIO 54.98
- GSIW 60.23
- Support Level
- PHIO $1.71
- GSIW $0.70
- Resistance Level
- PHIO $2.08
- GSIW $0.77
- Average True Range (ATR)
- PHIO 0.13
- GSIW 0.12
- MACD
- PHIO 0.01
- GSIW 0.00
- Stochastic Oscillator
- PHIO 76.32
- GSIW 48.50
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.